Replies to post #160911 on Cytodyn Inc (CYDY)

[DonDonDonDon]

Leronlimab's detractors love to hammer on the P-Value of Primary End Points in Leronlimab studies. That's because they have ZERO credible ammunition to train on the science behind what Leronlimab does to the patients in those studies.

All that matters is data. It makes no sense to say that leronlimab failed its trials but still works because "science".